oncologyhigh engagement
NCI keeps pushing immunotherapy and targeted therapy trials forward
A broad cluster of National Cancer Institute-led recruiting and active trials spans AML, lung, melanoma, breast, gastric/esophageal, Hodgkin lymphoma, Waldenstrom macroglobulinemia, upper urinary tract cancer, pancreatic cancer, and EGFR-mutant lung cancer. The common thread is continued late-stage evaluation of immunotherapy, targeted therapy, and biomarker-driven treatment strategies across major cancer types.
Draft a post from this →health-datamedium engagement
Tempus and NIH keep funding the data rails behind precision medicine
Tempus AI's S-4/A filing and NIH-funded bioinformatics infrastructure signals point to growing investment in data platforms, analytics, and research-enablement tooling in healthcare. This is less about a single clinical product and more about the rails supporting precision medicine, trial matching, and biomedical data management.
Draft a post from this →nih-fundinglow engagement
NIH backs rehab engineering and nervous system restoration cores
Several NIH awards support infrastructure and program cores at VA and academic institutions, including wheelchair and rehabilitation engineering, restoration of nervous system function, and a smartphone-plus-medications approach for heavy drinking. These signals reflect steady federal support for translational and rehabilitation-oriented medical technology research.
Draft a post from this →diagnosticslow engagement
Serology testing market growth keeps the diagnostics story alive
A market report on serology testing underscores continued expansion in diagnostic testing demand, with growth projections through 2033. While not a device-specific announcement, it reinforces durable interest in testing infrastructure and lab-facing medical technology.
Draft a post from this →